Latest Cost Savings News

Galilee Energy has commenced drilling its Zydeco-1 well in Louisiana, executing a cost-optimised plan targeting up to 13.7 billion cubic feet of gas and 610,000 barrels of condensate, marking a key milestone in its US Gulf Coast expansion.

Anson Resources has dramatically expanded its Green River Lithium Project resource and confirmed robust project economics, while sealing a key agreement with POSCO for a demonstration plant funded by the Korean industrial giant.

Xenitra Limited (ASX:XEN) has turned around its cash flow in Q4 FY26, reporting positive operating cash flow of A$0.8 million driven by a leaner cost base and a shift towards higher-margin OTC medicines and blockchain-enabled OPAL tokenised sales.

Volt Group has delivered a record $5.1 million in half year revenue receipts for HY26, more than doubling prior year results, driven by strong contributions from its 4D Delta acquisition and solid performances across Wescone and EcoQuip.

Appen's Q2 FY26 results highlight a robust 26% revenue increase, driven by a 75% jump in its China segment and improving global operations. The company reiterates its full-year guidance amid ongoing AI market growth and operational efficiencies.

Green360 Technologies has sealed its first binding supply contract with Holcim and ramped up MKX production, positioning itself as Australia’s leading supplier of low-carbon cement alternatives amid tightening SCM markets.

Elixinol Wellness posted a record quarterly revenue of $4.3 million in Q2 FY26, driven by The Healthy Chef's expansion and a 45% gross margin. Cost cuts helped deliver positive underlying operating cash flow for the third straight quarter despite some one-off expenses.

Whitehaven Coal delivered a robust finish to FY26, hitting top-end guidance for production and sales while improving safety and reducing costs.

Blackpearl Group reported a 95% year-on-year ARR increase to $27.2 million in Q1 FY27, alongside a strategic shift to higher-quality revenue and a clear path to reducing EBITDAF losses through FY27. The company also launched its Platform as a Service offering ahead of schedule, underpinning its evolving revenue model.

Adherium reports a near tenfold surge in recurring revenue from remote patient monitoring and clinical evidence supporting significant cost reductions in respiratory care.

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

The Star Entertainment Group reported a significant improvement in quarterly EBITDA loss alongside stable revenue, completing key joint venture exit and refinancing milestones that boosted liquidity to $267 million.